Related Experiment Video
Updated: May 30, 2026

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate (NMDA) Receptor in Blood
Published on: January 9, 2018
Encephalitis associated with glutamic acid decarboxylase autoantibodies in a child: a treatable condition?
Christian M Korff1, Paloma Parvex, Laurent Cimasoni
1Pediatric Neurology, Pediatric Specialties Service, University Hospital of Geneva, Switzerland. christian.korff@hcuge.ch
Insights
Glutamic acid decarboxylase (GAD) antibody-related encephalitis is a severe condition causing seizures and developmental regression in children. Early immunomodulatory treatment with plasmapheresis and rituximab shows promise for significant clinical improvement.
Area of Science:
- Pediatric Neurology
- Neuroimmunology
- Autoimmune Encephalitis
Background:
- Glutamic acid decarboxylase autoantibodies (GADA) are implicated in autoimmune encephalitis.
- Recognition of GADA-related encephalitis in childhood is crucial for timely intervention.
Observation:
- A 6-year-old girl presented with refractory seizures, developmental regression, and type 1 diabetes mellitus.
- Diagnostic workup included extensive blood analysis, EEG, MRI, PET, and lumbar puncture.
Findings:
- Highly elevated GADA titers were detected in serum and cerebrospinal fluid.
- Treatment with plasmapheresis and rituximab led to major clinical improvement and decreased antibody levels.
Implications:
- GADA-related encephalitis is a severe, potentially reversible epileptic disorder in children.
- Aggressive immunomodulatory therapy, including plasmapheresis and rituximab, is effective.
- Further studies are needed to ascertain if early treatment ensures complete remission.
Objective:
To increase the recognition of glutamic acid decarboxylase autoantibodies-related encephalitis in childhood.
Design:
Case report and review of the literature.
Patient:
A 6-year-old girl who had developed refractory seizures, developmental regression, and type 1 diabetes mellitus at age 25 months.
Interventions:
Blood analysis, electroencephalogram, cerebral magnetic resonance imaging, positron emission tomography scan, lumbar puncture, and measurement of glutamic acid decarboxylase activity were performed. Treatment with repeated plasmapheresis and rituximab, with concomitant antiepileptic drugs, was administered.
Results:
Highly elevated titers of glutamic acid decarboxylase autoantibodies were found in the serum, as well as in the cerebrospinal fluid. Major clinical improvement in parallel with a decrease in the levels of serum and cerebrospinal fluid antibodies was observed with treatment.
Conclusions:
Encephalitis associated with glutamic acid decarboxylase autoantibodies is a severe epileptic disorder that occurs in young children as well as adults. It may be partially reversible with aggressive immunomodulatory treatment, including plasmapheresis and rituximab. Studies are warranted to determine whether early treatment leads to complete remission.
More Related Videos
10:19High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
08:20Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
Published on: June 2, 2022
Related Concept Videos
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Antiepileptic Drugs: Glutamate Antagonists
Hepatic Encephalopathy
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Brain Abscess l: Introduction